HC Wainwright reiterated their buy rating on shares of Jaguar Health (NASDAQ:JAGX) in a research note published on Monday morning, AnalystRatings.com reports. The firm currently has a $3.00 target price on the biotechnology company’s stock, down from their previous target price of $10.00.
Several other analysts also recently commented on the stock. LADENBURG THALM/SH SH started coverage on shares of Jaguar Health in a research report on Thursday, September 12th. They issued a buy rating and a $5.00 target price for the company. ValuEngine raised shares of Jaguar Health from a hold rating to a buy rating in a research report on Thursday, November 14th. Finally, Zacks Investment Research raised shares of Jaguar Health from a hold rating to a buy rating and set a $1.00 target price for the company in a research report on Thursday, November 14th.
Jaguar Health stock traded down $0.03 during trading hours on Monday, hitting $0.64. The company had a trading volume of 501,800 shares, compared to its average volume of 558,277. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.88 and a quick ratio of 0.61. The firm has a market capitalization of $30.67 million, a P/E ratio of 0.00 and a beta of 0.71. Jaguar Health has a fifty-two week low of $0.61 and a fifty-two week high of $36.39. The firm’s fifty day moving average is $0.81 and its 200-day moving average is $1.77.
About Jaguar Health
Jaguar Health, Inc, a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc, focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.
See Also: Cash Asset Ratio
Receive News & Ratings for Jaguar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Health and related companies with MarketBeat.com's FREE daily email newsletter.